The company specializes in the development, manufacture and academic promotion of prescription medicines, with a focus on oncology, cardiovascular and metabolic diseases, and respiratory diseases, and its products are available in more than 100 countries and regions around the world. [1]
On April 26, 2021, the European Commission said it had initiated legal proceedings against AstraZeneca for non-compliance with a contract for the supply of the New Crown vaccine and for not having a credible plan to ensure delivery of the vaccine.
Since entering China in 1993, AstraZeneca has been putting science first and focusing on innovation to meet the country's growing healthcare needs and to realize its ambitious vision of "pioneering innovation for the benefit of patients and becoming a trusted healthcare partner in China". Headquartered in Shanghai, AstraZeneca employs over 10,000 people in China and generated sales of US$2.96 billion in 2017. The company has invested more than US$750 million in China,[2] with manufacturing bases in Wuxi and Taizhou, and a China logistics center in Wuxi. In China, AstraZeneca's business focuses primarily on the therapeutic areas most needed by Chinese patients, including cardiovascular, metabolic diseases, oncology, respiratory, gastroenterology and anesthesia. Achieving leadership in R&D[5]
AstraZeneca is an innovation-driven global biopharmaceutical company focused on developing, manufacturing and marketing prescription medicines to bring about far-reaching change in the healthcare industry. Research and development and patients are at the heart of what we do, focusing our strengths and resources on therapeutic areas where we can make a real difference. We are committed to "pushing the boundaries of science to develop life-changing medicines". Our business strategy sets out the path to success: to be China's most trusted healthcare partner by pioneering innovations that benefit patients. [5]
Accelerating growth[6]
With global standards of excellence, a deep understanding of the local market and continued investment, AstraZeneca China is committed to delivering high quality medicines to more Chinese patients in a faster way to meet the country's growing healthcare needs. [6]AstraZeneca China's headquarters in Shanghai's Zhangjiang Hi-Tech Park houses a number of functions, including a research and development center, and has manufacturing sites in Wuxi and Taizhou. [7]
Becoming a great place to work